1. BLOCKADE OF THE PD‐1 CHECKPOINT WITH ANTI–PD‐L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL). (June 2017) Authors: Chen, R.; Gibb, A.L.; Collins, G.P.; Popat, R.; El‐Sharkawi, D.; Burton, C.; Lewis, D.; Miall, F.M.; Forgie, A.; Compagnoni, A.; Andreola, G.; Brar, S.; Thall, A.; Woolfson, A.; Radford, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P918: HIGH RESPONSES RATES WITH SINGLE AGENT BELANTAMAB MAFODOTIN IN RELAPSED SYSTEMIC AL AMYLOIDOSIS. (23rd June 2022) Authors: Khwaja, J.; Bomsztyk, J.; Mahmood, S.; Wisniowski, B.; Shah, R.; Tailor, A.; Yong, K.; Popat, R.; Rabin, N.; Kyriakou, C.; Sive, J.; Worthington, S.; Hart, A.; Dowling, E.; Correia, N.; Bygrave, C.; Rydzewski, A.; Jamroziak, K.; Wechalekar, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 808 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1. (23rd June 2022) Authors: Martínez-López, J.; Moreau, P.; Usmani, S. Z.; Garfall, A.; van de Donk, N. W.; San-Miguel, J. F.; Oriol, A.; Chari, A.; Karlin, L.; Mateos, M.-V.; Popat, R.; Nooka, A. K.; Sidana, S.; Trancucci, D.; Verona, R.; Girgis, S.; Uhlar, C.; Stephenson, T.; Banerjee, A.; Krishnan, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 811 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1. (23rd June 2022) Authors: Popat, R.; Moreau, P.; Usmani, S. Z.; Garfall, A.; Mateos, M.-V.; San-Miguel, J. F.; Oriol, A.; Nooka, A. K.; Rosinol, L.; Chari, A.; Karlin, L.; Krishnan, A.; Bahlis, N.; Martin, T.; Besemer, B.; Martínez-López, J.; Delforge, M.; Fastenau, J.; Gries, K. S.; van de Donk, N. W. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 812 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P941: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-6 ARM-A INTERIM ANALYSIS. (23rd June 2022) Authors: Quach, H.; Gironella, M.; Lee, C.; Popat, R.; Cannell, P.; Kasinathan, R. S.; Chopra, B.; Rogers, R.; Ferron-Brady, G.; Shafi-Harji, S.; Patel, N.; Opalinska, J.; Gupta, I.; Augustson, B. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 831 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P954: ESTABLISHING THE NATIONAL INSTITUTE FOR HEALTH RESEARCH (NIHR) HEALTH INFORMATICS COLLABORATIVE (HIC) MULTIPLE MYELOMA (MM) REGISTRY. (23rd June 2022) Authors: Tayabali, S.; Moore, S.; Jenner, M.; Djebbari, F.; Romao, L.; English, L.; Rodriguez, R.; Briot Ribeyre, B.; Roadknight, G.; Varnai, K.; Little, S.; Davies, J.; Woods, K.; Davis, C.; Borca, F.; Olza Meneses, J.; Phan, H.; Wong, W. K.; Popat, R. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 844 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (23rd June 2022) Authors: Fonseca, R.; Kuroda, J.; Ishida, T.; Popat, R.; Huang, J. S.; Yver, A.; Vandendries, E.; Elmeliegy, M.; Ma, W. D.; Sborov, D. W. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1903 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (23rd June 2022) Authors: Dekhtiarenko, I.; Lelios, I.; Attig, J.; Sleiman, N.; Lazzaro, D.; Clausen, I.; Gräfe, N.; Helms, H.-J.; Schindler, E.; Belli, S.; Fauti, T.; Eckmann, J.; Umana, P.; Jacob, W.; Schneider, M.; Hasselbalch Riley, C.; Hutchings, M.; Yoon, S.-S.; Koh, Y; Manier, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL. (23rd June 2022) Authors: Hasselbalch Riley, C.; Hutchings, M.; Yoon, S.-S.; Koh, Y.; Manier, S.; Facon, T.; Harrison, S. J.; Er, J.; Volzone, F.; Pinto, A.; Montes, C.; Ocio, E. M.; Alfonso-Pierola, A.; Rodriguez Otero, P.; Offner, F.; Guidetti, A.; Corradini, P.; Titouan, C.; Hulin, C.; Touzeau, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. TAK‐659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT‐3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE‐ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY. (June 2017) Authors: Kaplan, J.; Gordon, L.; Infante, J.; Popat, R.; Rambaldi, A.; Madan, S.; Patel, M.R.; Gritti, G.; El‐Sharkawi, D.; Chau, I.; Radford, J.; Perez De Oteyza, J.; Zinzani, P.; Iyer, S.; Faucette, S.; Sheldon‐Waniga, E.; Stumpo, K.; Shou, Y.; Carpio, C.; Bosch, F. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗